Study of Kinetics & Efficacy of the Immune Response Against COVID-19 Among

Status Completed

Clinical Trial Summary

COVID-19 is a pathology linked to the SARS-CoV-2 virus, a new virus of the coronaviridae family that emerged in China in December 2019 before rapidly becoming a pandemic according to the WHO on March 11, 2020. The epidemic affected France from February 2020. On February 24, a patient hospitalized at Percy hospital was the cause of a major nosocomial epidemic, potentially responsible for more than 250 symptomatic people in the hospital as of April 6. The outbreak was identified by Percy hospital management on March 16, and barrier measures were immediately put in place. From March 20, a mixed investigation unit set up a chain of nasopharyngeal swabs for Percy hospital staff. A COVID-19 case reporting unit was set up at Percy hospital in response to the identification of the outbreak within the hospital. This unit carried out rapid identification and regular follow-up until the return to work of the staff. Thus all symptomatic patients are identified and the COVID-19 case census cell will follow all Percy hospital staff, including volunteers recruited to deal with the epidemic, throughout the duration of the epidemic. This population, captive by nature, will be one of the few described in the world during this epidemic. Current data on short-, medium- and long-term immunity induced by COVID-19 infection are fragmentary, as is the existence of a large asymptomatic population, making it difficult to cut the chains of transmission in the absence of an effective diagnostic tool. Another important issue is the quality of immunity induced by the infection, as it conditions the future of the pandemic, which could become endemic and recurrent if immunity were not sterilizing. As yet unpublished data in primates show that in the primate model re-infection is not possible in the short term, while patients cured from the Wuhan epidemic seem to be detected again positive for virus shedding. The objective of this study is to characterize the immunity (systemic and local) induced by SARS-Cov-2 infection among Percy hospital staff who are at high risk of contamination even in a period of confinement.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Sars-CoV2

Clinical Trial Details

NCT number	NCT04408001
Study type	Observational
Source	Direction Centrale du Service de Santé des Armées
Contact
Status	Completed
Phase
Start date	June 4, 2020
Completion date	March 15, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT04446065` - Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers	Phase 2/Phase 3
Completed	`NCT04419025` - Efficacy of N-Acetylcysteine (NAC) in Preventing COVID-19 From Progressing to Severe Disease	Phase 2
Not yet recruiting	`NCT04400019` - Prevention of COVID19 Infection in Nursing Homes by Chemoprophylaxis With Hydroxychloroquine (PREVICHARM)	Phase 2/Phase 3
Completed	`NCT04463004` - Mavrilimumab to Reduce Progression of Acute Respiratory Failure in COVID-19 Pneumonia and Systemic Hyper-inflammation	Phase 2
Completed	`NCT04446429` - Anti-Androgen Treatment for COVID-19	N/A
Completed	`NCT04402957` - LSALT Peptide vs. Placebo to Prevent ARDS and Acute Kidney Injury in Patients Infected With SARS-CoV-2 (COVID-19)	Phase 2
Recruiting	`NCT04441372` - Prognostication of Oxygen Requirement in Non-severe SARS-CoV-2 Infection
Recruiting	`NCT04581148` - SARS-CoV2 Antibodies in Pediatric Patients (COVID-19)
Completed	`NCT04530604` - Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)	Phase 1
Terminated	`NCT04371978` - Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Diabetic Patients With Established COVID-19	Phase 3
Active, not recruiting	`NCT04635605` - Methylene Blue Treatment of COVID-19	Phase 2
Recruiting	`NCT04395599` - Risk of Air Contamination During Visceral Surgery in COVID19 Patients	N/A
Recruiting	`NCT04472585` - Efficacy of Subcutaneous Ivermectin With or Without Zinc in COVID-19 Patients	Phase 1/Phase 2
Active, not recruiting	`NCT04411433` - Efficacy and Safety of Hydroxychloroquine and Favipiravir in the Treatment of Mild to Moderate COVID-19	Phase 3
Completed	`NCT04359706` - Bacterial and Fungal Microbiota of Patients With Severe Viral Pneumonia With COVID-19
Recruiting	`NCT04395794` - SARS-CoV-2 Disguise Study
Completed	`NCT04386551` - Detection of COVID-19 in Saliva Collection
Recruiting	`NCT04403269` - NORMAL HUMAN IMMUNOGLOBULINS (IVIG) IN PATIENTS AGED 75 YEARS AND OVER, COVID-19 WITH SEVERE ACUTE RESPIRATORY FAILURE	Phase 2
Withdrawn	`NCT04379492` - A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19	Phase 2
Not yet recruiting	`NCT04377646` - A Study of Hydroxychloroquine and Zinc in the Prevention of COVID-19 Infection in Military Healthcare Workers	Phase 3

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Study of Kinetics and Efficacy of the Immune Response Against COVID-19 Among Hospital Staff — IMMUNO-COVID

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms